代谢组学特征可预测个体多病种结局
研究利用英国生物银行117,981名参与者的核磁共振代谢组学数据训练神经网络,学习疾病特异性代谢状态,并在四个独立队列中验证。代谢状态与除乳腺癌外所有研究疾病的发病事件率相关,年龄、性别与代谢状态联合可等同或优于既有预测因子,并为八种常见疾病提供额外预测信息,决策曲线分析显示预测改善在广泛阈值范围内具有临床效用。
要点
- 基于168个循环代谢标志物训练的神经网络可捕捉疾病特异性代谢状态。
- 年龄、性别与代谢状态联合对15个终点的10年结局预测等同或优于既有预测因子。
- 代谢状态在八种常见疾病上为全面临床变量提供额外预测信息。
核心结论
- 核磁共振衍生代谢组学特征作为多病种检测手段,在同时提示多种常见疾病风险方面兼具潜力与局限性。
研究设计与样本
- 模型在四个独立队列中进行验证。
主要发现
- 代谢状态与所有研究疾病的发病事件率相关,乳腺癌除外。
- 对15个终点的10年结局预测,年龄、性别与代谢状态的联合等同或优于既有预测因子。
- 代谢状态在包括2型糖尿病、痴呆和心力衰竭在内的八种常见疾病上,为全面临床变量提供额外预测信息。
- 决策曲线分析显示,预测改善在广泛潜在决策阈值范围内转化为临床效用。
局限性
- 原文指出该研究展示了核磁共振衍生代谢组学特征作为多病种检测手段的潜力与局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Risk stratification is critical for the early identification of high-risk individuals and disease prevention. Here we explored the potential of nuclear magnetic resonance (NMR) spectroscopy-derived metabolomic profiles to inform on multidisease risk beyond conventional clinical predictors for the onset of 24 common conditions, including metabolic, vascular, respiratory, musculoskeletal and neurological diseases and cancers. Specifically, we trained a neural network to learn disease-specific metabolomic states from 168 circulating metabolic markers measured in 117,981 participants with ~1.4 million person-years of follow-up from the UK Biobank and validated the model in four independent cohorts. We found metabolomic states to be associated with incident event rates in all the investigated conditions, except breast cancer. For 10-year outcome prediction for 15 endpoints, with and without established metabolic contribution, a combination of age and sex and the metabolomic state equaled or outperformed established predictors. Moreover, metabolomic state added predictive information over comprehensive clinical variables for eight common diseases, including type 2 diabetes, dementia and heart failure. Decision curve analyses showed that predictive improvements translated into clinical utility for a wide range of potential decision thresholds. Taken together, our study demonstrates both the potential and limitations of NMR-derived metabolomic profiles as a multidisease assay to inform on the risk of many common diseases simultaneously.
引用
- Buergel T, Steinfeldt J, Ruyoga G, et al. Metabolomic profiles predict individual multidisease outcomes. Nat Med. 2022. PMID: 36138150. doi:10.1038/s41591-022-01980-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。